GlassScriptPhysician profile
Brian P Shortal
NPI 1356331961
$9,398.59
in general payments reported to CMS, 2019-2025
26 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $154 · 2021: $1,034 · 2022: $2,322 · 2023: $1,472 · 2024: $2,317 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,190 · Consulting Fee: $275 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,190.02 |
| Consulting Fee | $275.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,700.00 | 2022-2024 | |
| Novo Nordisk INC | $1,404.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $1,220.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.68 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $816.84 | 2019-2025 | Xarelto, Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $558.43 | 2019-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $549.62 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $449.24 | 2019-2024 | Repatha |
| Abbott Laboratories | $341.03 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $311.62 | 2021-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| Pfizer INC. | $267.24 | 2019-2025 | |
| Edwards Lifesciences Corporation | $161.66 | 2022 | |
| Lantheus Medical Imaging, INC. | $127.95 | 2023-2025 | Definity |
| Alnylam Pharmaceuticals INC. | $104.81 | 2024-2025 | Onpattro |
| Janssen Scientific Affairs, LLC | $102.62 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $100.15 | 2024-2025 | Watchman Flx |
| Bridgebio Pharma, INC. | $58.06 | 2025 | Attruby |
| Becton, Dickinson and Company | $45.00 | 2024 | Bd Introsyte |
| Merck Sharp & Dohme LLC | $41.82 | 2024-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $34.70 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $30.40 | 2023 | |
| Ethicon US, LLC | $29.12 | 2025 | Surgicel Nu-Knit, Evarrest, Surgiflo Hemostatic Matrix |
| Ionis Pharmaceuticals, INC. | $23.77 | 2025 | Tryngolza |
| Scpharmaceuticals INC. | $21.17 | 2024 | |
| Vital Connect, INC | $20.56 | 2025 | Vitalpatch Rtm |
| Bayer Healthcare Pharmaceuticals INC. | $20.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shortal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.